https://www.selleckchem.com/products/BIBF1120.html
99, 95% C.I. (Confidence Interval) 1.45-2.68; p less then 0.0001). Modeling of lipids by class (sphingolipids, acylcarnitines and lysophosphatidylcholines) revealed a median OS = 5.7 months vs. 11. 9 months for the high vs. low risk group. (HR 2.23, 95% C.I. 1.55-3.20; p less then 0.0001). These results demonstrate that metabolic profiles from pre-treatment samples may be useful to stratify clinical outcomes for mNSCLC patients receiving chemotherapy. Genomic and longitudinal measurements pre- and post-treatment may yield addition info
Like
Comment
Share
